HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α

References

• Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018;10:6823–6833. doi:10.2147/CMAR.S18517630573992
   PubMed Web of Science ®Google Scholar
• Vazquez Rodriguez G, Abrahamsson A, Jensen LD, Dabrosin C. Estradiol promotes breast cancer cell migration via recruitment and activation of neutrophils. Cancer Immunol Res. 2017;5(3):234–247. doi:10.1158/2326-6066.CIR-16-015028159748
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(1):69–90. doi:10.3322/caac.2010721296855
   PubMedGoogle Scholar
• Huang ZZ, Chen WQ, Wu CX, et al. Incidence and mortality of female breast cancer in China, a report from 32 Chinese cancer registries, 2003-2007. Tumor. 2012;32:435–439.
   Google Scholar
• Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res. 2014;20(4):782–790. doi:10.1158/1078-0432.CCR-13-058324536073
   PubMed Web of Science ®Google Scholar
• Shan NL, Wahler J, Lee HJ, et al. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation with triple negative breast cancer. J Steroid Biochem Mol Biol. 2017;173(1):122–129. doi:10.1016/j.jsbmb.2016.12.00127923595
   PubMedGoogle Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer, challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi:10.1038/nrclinonc.2016.6627184417
   PubMed Web of Science ®Google Scholar
• Pogoda K, Niwinska A, Murawska M, Pienkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388. doi:10.1007/s12032-012-0388-423292831
   PubMed Web of Science ®Google Scholar
• Pal S, Luchtenborg M, Davies EA, Jack RH. The treatment and survival of patients with triple negative breast cancer in London population. Springerplus. 2014;3(1):553. doi:10.1186/2193-1801-3-55325324980
   PubMedGoogle Scholar
• Ji P, Zhang Y, Wang SJ, et al. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs. Oncol Rep. 2016;35(6):3293–3302. doi:10.1186/bcr210627109463
   PubMed Web of Science ®Google Scholar
• Laranjo M, Carvalho MJ, Costa T, et al. Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype. Breast. 2018;38(1):22–29. doi:10.1016/j.breast.2017.11.00929182983
   PubMedGoogle Scholar
• Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–1270. doi:10.1101/gad.106180312756227
   PubMed Web of Science ®Google Scholar
• Wahler J, So JY, Cheng LC, Maehr H, Uskokovic M, Suh N. Vitamin D compounds reduce mammoshpere formation and decrease expression of putative stem cell markers in breast cancer. J Steroid Biochem Mol Biol. 2015;148(1):148–155. doi:10.1016/j.jsbmb.2014.10.01625445919
   PubMedGoogle Scholar
• Ma F, Li H, Shi X, et al. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353(2):153–159. doi:10.1016/j.canlet.2014.06.02225130168
   PubMed Web of Science ®Google Scholar
• Rappa G, Lorico A. Phenotypic characterization of mammosphere forming cells from the human MA-11 breast cancinoma cell line. Exp Cell Res. 2010;316(9):1576–1586. doi:10.1016/j.yexcr.2010.01.01220074564
   PubMed Web of Science ®Google Scholar
• Grimshaw MJ, Cooper L, Papazisis K, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008;10(3):R52. doi:10.1186/bcr210618541018
   PubMed Web of Science ®Google Scholar
• Ma R, Karthik GM, Lovrot J, et al. Estrogen receptor beta as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017;109(3):1–14. doi:10.1093/jnci/djw236
   PubMedGoogle Scholar
• Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9(11):1623–1636. doi:10.2217/fon.13.9224156323
   PubMed Web of Science ®Google Scholar
• Wang W, He YF, Sun QK, et al. Hypoxia-inducible factor 1α in breast cancer prognosis. Clin Chim Acta. 2014;428(1):32–37. doi:10.1016/j.cca.2013.10.01824482805
   PubMedGoogle Scholar
• Nemeth MJ, Gurtis DJ, Kirby MR, et al. Hmgb3: an HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation. Blood. 2003;102(4):1298–1306. doi:10.1182/blood-2002-11-354112714519
   PubMed Web of Science ®Google Scholar
• Costa-Sliva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–826. doi:10.1038/ncb316925985394
   PubMed Web of Science ®Google Scholar
• Gao J, Zou Z, Gao J, et al. Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):345–352.25755721
   PubMed Web of Science ®Google Scholar
• Gong Y, Cao Y, Song L, Zhou J, Wang C, Wu B. HMGB3 characterization in gastric cancer. Genet Mol Res. 2013;12(4):6032–6039. doi:10.4238/2013.December.2.124338397
   PubMed Web of Science ®Google Scholar
• Staal FJ, de Ridder D, Szczepanski T, et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates in involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia. 2010;24(3):491–499. doi:10.1038/leu.2009.28620072147
   PubMed Web of Science ®Google Scholar
• Li X, Wu Y, Liu A, Tang X. MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. Biochem Biophys Res Commun. 2016;477(4):768–773. doi:10.1016/j.bbrc.2016.06.13327363334
   PubMed Web of Science ®Google Scholar
• Elgamal OA, Park JK, Gusev Y, et al. Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013;8(10):e76402. doi:10.1371/journal.pone.007640224098490
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chang Y, Zhang J, et al. HMGB3 promotes growth and migration in colorectal cancer by regulating WNT/β-catenin pathway. PLoS One. 2017;12(7):e0179741. doi:10.1371/journal.pone.017974128678825
   PubMed Web of Science ®Google Scholar
• Nemeth MJ, Kirby MR, Bodine DM. HMGB3 regulates the balance between hematopoietic stem cell self-renewal and differentiation. Proc Natl Acad Sci USA. 2006;103(37):13783–13788. doi:10.1073/pnas.060400610316945912
   PubMed Web of Science ®Google Scholar
• Wang L, Zhai W, Yang X, et al. Lentivirus-mediated stable Fas gene silencing in human umbilical cord-derived mesenchymal stem cells. Nan Fang Yi Ke Da Xue Bao. 2014;34(10):1475–1480.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−△△ct method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Shaw FL, Harrison H, Spence K, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012;17(2):11–117. doi:10.1007/s10911-012-9255-3
   Web of Science ®Google Scholar
• So JY, Lee HJ, Smokarek AK, et al. A novel gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol. 2011;79(3):360–367. doi:10.1124/mol.110.06840321115634
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yu Q, Liu Y, et al. Dual receptor targeting cell penetrating peptide modified liposome for glioma and breast cancer postoperative recurrence therapy. Pharm Res. 2018;35(7):130. doi:10.1007/s11095-018-2399-029700620
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Yan T, Calle AS, et al. iPSC-derived cancer stem cells provide a model of tumor vasculature. Am J Cancer Res. 2016;6(9):1906–1921.27725898
   PubMed Web of Science ®Google Scholar
• Zhu X, Rao X, Yao W, Zou X. Downregulation of MiR-196b-5p impedes cell proliferation and metastasis in breast cancer through regulating COL1A1. Am J Transl Res. 2018;10(10):3122–3132.30416655
   PubMed Web of Science ®Google Scholar
• Petit A, Ragu C, Della-Valle V, et al. NUP98-HMGB2: a novel oncogenic fusion. Leukimia. 2010;24(3):654–658. doi:10.1038/leu.2009.241
   PubMed Web of Science ®Google Scholar
• Li M, Cai Y, Zhao H, et al. Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients. Tumor Biol. 2015;36(6):4785–4792. doi:10.1007/s13277-015-3130-y
   PubMedGoogle Scholar
• Zheng WJ, Yao M, Fang M, Wang L, Dong ZZ, Yao DF. Abnormal expression of HMGB3 is significantly associated with malignant transformation of hepatocytes. World J Gastroenterol. 2018;24(32):3650–3662. doi:10.3748/wjg.v24.i32.365030166860
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Y, Tang T, et al. Transcriptome profiling of panc-1 spheroid cells with pancreatic cancer stem cells properties cultured by a novel 3D semi-solid system. Cell Physiol Biochem. 2018;47(5):2109–2125. doi:10.1159/00049147929975934
   PubMedGoogle Scholar
• Katsukawa M, Nakajima Y, Fukumoto A, Doi D, Takahashi J. Fail-safe therapy by gamma-ray irradiation against tumor formation by human induced pluripotent stem cell-derived neural progenitors. Stem Cell Dev. 2016;25(11):815–825. doi:10.1089/scd.2015.0394
   PubMed Web of Science ®Google Scholar
• Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507. doi:10.1038/ng.12718443585
   PubMed Web of Science ®Google Scholar
• Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154–1159.15709183
   PubMed Web of Science ®Google Scholar
• Ho CM, Lee FK, Huang SH, Cheng WF. Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary. Am J Cancer Res. 2018;8(1):56–69.29416920
   PubMed Web of Science ®Google Scholar
• Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated mA-demethylation of NANONG mRNA. Proc Natl Acad Sci USA. 2016;113(14):E2047–E2056. doi:10.1073/pnas.160288311327001847
   PubMed Web of Science ®Google Scholar
• Cai X, Ding H, Liu Y, et al. Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of warburg effect in pancreatic cancer. Acta Biochem Biophys Sin (Shanghai). 2017;49(2):119–127.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan J, Wang L, et al. HIF-1 alpha promotes breast cancer cell MCF7 proliferation and invasion through regulating miR-210. Cancer Biother Radiopharm. 2017;32(8):297–301. doi:10.1089/cbr.2017.227029053417
   PubMed Web of Science ®Google Scholar